ClinicalTrials.gg
RecruitingNCT07018570Updated Nov 2, 2026

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

A Phase 2 interventional study of Pembrolizumab and Docetaxel in Gastroesophageal Junction (GEJ) Adenocarcinoma, sponsored by National Cancer Center Hospital East. Recruiting at 1 site in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by National Cancer Center Hospital East · Phase 2, Interventional, and Treatment

How we know · 11 judgments

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies testing pembrolizumab in Adenocarcinoma — 3 open to participants now, 5 under way, none of them phase 3. pembrolizumab · Adenocarcinoma.

Planned enrollment
7th of 13
26 · median 26
Started
2025
the only one that year
Phase 2
12 of 13
3 open now
Registered
12th of 13
by date
Lead sponsor
1 of 13
National Cancer Center Hospital East

Among the 13 studies testing pembrolizumab in Adenocarcinoma, this one is the 7th largest by planned enrollment, is the only one that started in 2025, is one of 12 in phase 2, and was the 12th registered.

Adenocarcinoma

622 studies on the registry are indexed under Adenocarcinoma; 149 are open to participants now.

Browse Adenocarcinoma studies →

Open to participants now

3 of the 13 studies testing pembrolizumab in Adenocarcinoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 113 Adenocarcinoma studies recruiting now, 84 (74%) set no upper age limit and 11 (10%) stop at 75 or younger; 7 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing pembrolizumab in Adenocarcinoma, or all of them as a file.
02

Study summary

This study is to evaluate the effectiveness of treatment for esophagogastric junction carcinoma, total neoadjuvant therapy (TNT) including pembrolizumab and FLOT is conducted, aiming to choose between surgery or organ preservation treatment strategies.

Read the detailed description

In Immunochemotherapy before short-term radiation therapy, pembrolizumab 200mg will be intravenously infused at 21-day intervals for 2 doses. FLOT (docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200mg/m2, 5-FU 2600 mg/m2) will be intravenously infused at 14-day intervals for 2 doses.

Regarding short-term radiotherapy, irradiation will be delivered from day1 to day5, with a dose of 5 Gy per fraction for a total of 25 Gy.

In Immunochemotherapy after short-term radiation therapy, pembrolizumab 200mg will be intravenously infused on day 8. FLOT will be intravenously infused on day 1 and day15.

If CR or Near CR is achieved after the first and second efficacy assessment, pembrolizumab 200mg will be intravenously infused at 21-day intervals for 14 doses and FLOT will be intravenously infused at 14-day intervals for 4 doses as immunochemotherapy as non-operative management (NOM).

If CR or Near CR is not achieved after the first or second efficacy assessment, surgery will be performed. And then pembrolizumab 200mg will be intravenously infused at 21-day intervals for 14 doses and FLOT will be intravenously infused at 14-day intervals for 4 doses as Postoperative adjuvant immunochemotherapy.

03

Conditions studied

  • Gastroesophageal Junction (GEJ) Adenocarcinoma

Browse trials for

Keywords

  • Esophagogastric junction carcinoma
  • Total neoadjuvant therapy
  • TNT
  • Radiation
  • Surgery
  • Pembrolizumab
  • FLOT
  • Chemotherapy
  • Non-operative management
  • QOL
  • Phase II
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

\<Inclusion Criteria>

  1. Patients with confirmed esophagogastric junction adenocarcinoma.
  2. Patients who are naive to systemic therapy and have esophagogastric junction carcinoma of Siewert Type I to III classified as T: 2-4, N: any, and M: 0 according to the 8th edition of the UICC-TNM classification.
  3. Patients aged 18 years or older as of the day of .
  4. Patients with Performance Status (PS) 0 or 1.
  5. Patients whose most recent laboratory values within 14 days before registration meet all of the following criteria (testing on the same day of the week two weeks before the date of registration is acceptable).

[1] ≥1,500/mm3 [2] ≥9.0 g/dL [3] counts ≥100,000/mm3 [4] Total ≤1.5 mg/dL [5] (GOT) ≤100 IU/L [6] ALT (GPT) ≤100 IU/L [7] Serum creatinine ≤1.5 mg/dL 6) Patients who did not receive blood transfusion within 7 days before registration (ineligible if transfusion was performed on the same day of the week one week before the date of registration).

7)Female patients of who tested negative for pregnancy within 14 days before registration. Male and female patients who have agreed to practice appropriate highly effective with low user dependency during the study and for up to 120 days after discontinuation of the drug.

8)Patients who have given consent to provide samples for biomarker analysis. 9)Patients who have given their own written consent to participate in the study

\<Exclusion Criteria>

  1. Patients with a history of using an , anti-PD-L1, or anti-PD-L2 antibody.
  2. Patients with a history of acute coronary syndrome (including myocardial infarction and angina unstable), coronary angioplasty, or stent implantation within 6 months before registration.
  3. Patients with a history or findings of congestive heart failure of Class II or higher according to the (NYHA) classification of cardiac function.
  4. Patient with active double cancers [simultaneous double cancers and metachronous double cancers with a disease-free interval of ≤2 years. However, carcinoma in situ or lesions equivalent to intramucosal carcinoma judged to have been cured by local treatment shall not be included in active double cancers].
  5. Patients with serious (requiring hospitalization) complications (e.g., intestinal paralysis, intestinal obstruction, pulmonary fibrosis, difficult-to-control diabetes mellitus, cardiac failure, myocardial infarction, angina unstable, renal failure, hepatic failure, psychiatric disorder, cerebrovascular disorder).
  6. Patients with active (HBs antigen positive) or .
  7. Patients with a history of .
  8. Patients with complicated interstitial lung disease/pneumonitis or with a history of (non-infectious) interstitial lung disease/pneumonitis requiring administration.
  9. Patients who received a within 30 days before the start of investigational drug administration.
  10. Patients with concomitant disease or a history of chronic or recurrent autoimmune disease.
  11. Patients who require systemic corticosteroids (except for prophylactic administration for testing or allergic reactions, or temporary use to reduce edema associated with radiotherapy) or medication, or those who have received any of these treatments within 14 days before registration in this study.
  12. Patients with unhealed wounds (requiring sutures, antimicrobial administration, and cleaning procedures), ulcers, or fractures.
  13. Pregnant or lactating patients.
  14. Patients who are unwilling or unable to comply with the study protocol.
  15. Patients deemed by the investigator to be ineligible for this study.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
26 participants (estimated)

Study arms

  • Experimental
    Pembrolizumab plus FLOT, Ratiation

    Drug: Pembrolizumab · Drug: Docetaxel · Drug: Oxaliplatin · Drug: Levofolinate · Drug: Fluorouracil (5-FU) · Radiation: Radiation Therapy

Interventions

  • Pembrolizumab 200mg will be administered via intravenous infusion over 30 minutes, twice at 21-day intervals.

  • Docetaxel 50 mg/m2 will be administered over 60 minutes.

  • Oxaliplatin 85 mg/m2 will be administered over 2 hours.

  • DrugLevoleucovorinStudies of LevoleucovorinLevoleucovorin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Leucovorin 200 mg/m2 will be administered over 2 hours.

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5-FU 2600 mg/m2 will be administered over 24 hours.

  • RadiationRadiation Therapy

    25Gy (5Gy×5fr)

06

What researchers measure

Primary outcomes

  1. 3-year event-free survival (EFS) rate

    Time frame: 3 years

Secondary outcomes

  1. Organ-sparing survival

    Time frame: 3 years

  2. Overall survival (OS)

    Time frame: 3 years

  3. Clinical response rate

    Time frame: 3 years

  4. Clinical complete response rate

    Time frame: 3 years

  5. Major pathological response rate (MPR rate)

    Time frame: 3 years

  6. Pathological complete response rate (pCR rate)

    Time frame: 3 years

  7. R0 resection rate (R0 rate)

    Time frame: 3 years

  8. TNT completion rate

    Time frame: 3 years

  9. Treatment completion rate

    Time frame: 3 years

  10. Adverse event incidence rate

    Time frame: 3 years

  11. Post-treatment ctDNA clearance

    Time frame: 3 years

  12. EORTC QLQ-C30

    We are reporting scores from the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30). The scores were transformed to a 0-100 scale following the official EORTC scoring manual. For functional scales and global health status, higher scores indicate a better outcome. For symptom scales/items, higher scores indicate a worse outcome.

    Time frame: 3 years

  13. EORTC QLQ-OG25

    We are reporting scores from the EORTC QLQ-OG25 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Oesophago-Gastric module). The scores were transformed to a 0-100 scale following the official EORTC scoring manual. All scales and single items in the QLQ-OG25 are symptom-based. Therefore, higher scores indicate worse symptoms or poorer quality of life.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Jun 2030, 59 months after the start.

Of 71 non-industry phase 2 interventional studies under Adenocarcinoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 94. This study's planned 59 months is close to that.

Counting every sponsor, half of 93 studies reached it within 60 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2025
First posted
Jun 12, 2025
StartActual
Jul 24, 2025
Primary completionEst.
Jun 2030
CompletionEst.
Jun 2031
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07018570
Lead sponsor
National Cancer Center Hospital East
Responsible party
Kohei Shitara (Chief of Gastroenterology and Gastrointestinal Oncology Division, National Cancer Center Hospital East) — Principal investigator
First posted
Jun 12, 2025
Start date
Jul 24, 2025
Primary completion
Jun 2030 (estimated)
Completion
Jun 2031 (estimated)
Last update
Nov 2, 2026

Study contacts

Kohei Shitara, MD
Contact
pemflot-tnt@east.ncc.go.jp
+81-4-7133-1111 ext. 91520
Izuma Nakayama, MD
Contact
pemflot-tnt@east.ncc.go.jp
+81-4-7133-1111 ext. 92339

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion